Flavio Biccirè

The simultaneous presence of 4 #OCT high-risk features, although infrequent, was independently assoc w/ cardiac death or TS-MI on long-term follow-up. The presence of any TCFA was 5-fold as prevalent & similarly predictive of 5-yr adverse outcomes jacc.org/doi/10.1016/j.… #JACCINT

3-year data from the EuroCTO trial showed that PCI for chronic CTOs offers comparable long-term outcomes to medical therapy, with no significant difference in cardiovascular death or non fatal MI. #EIJBestOf ow.ly/vsAY50TxiLV

thanks @EricTopol for the interest in our plaque regression study with PCSK9i. The key point is that the level of plaque regression achieved in vessels is 2% (known already from main trial) but much more @ lesion level (5%) and at the most narrow spot of the vessel (10%).

Very intensive LDL cholesterol lowering achieved more coronary atherosclerotic plaque stability and regression. A post-hoc analysis of RCT PCSK-9 blocker + high dose statin vs high dose statin alone after heart attack jamanetwork.com/journals/jamac… @JAMACardio #ESCCongress2024 @RaberLorenz @FBiccire

🚨Breaking News: New ESC Guidelines on CCS. Intracoronary Imaging now Class IA for LM, true bifurcation and long lesions! Either OCT or IVUS. @PCRonline @escardio @NielsRHolm @twj1974 @nicolasamabile @FBiccire @ziadalinyc @hect2701 @sbrugaletta @HolgerNef